Latest News & Features
Big Pharma
Teva announced today that the European Commission has granted marketing authorisation for Cinqaero following an efficacy probe. 18 August 2016
Americas
The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report. 18 August 2016
Americas
Xycrobe Therapeutics revealed yesterday, August 17, that it has entered into a research agreement with pharmaceutical company Johnson & Johnson. 17 August 2016
Americas
The US Court of Appeals for the Federal Circuit has affirmed a ruling of the US Patent and Trademark Office that a patent challenged by Apotex is valid. 17 August 2016
Americas
The US Patent and Trademark Office has rejected the Broad Institute of MIT and Harvard’s request for a time extension before the start of its patent dispute surrounding the CRISPR technology. 16 August 2016
Africa
Eli Lilly has won a cybersquatting case in which the company successfully ordered the transfer of more than 200 domain names that purported to offer discounted erectile dysfunction drugs. 16 August 2016
Asia-Pacific
In Australia, laws governing the patentability of inventions directed to gene-based technology, including isolated naturally occurring and artificial gene sequences, are contentious. Unlike the US situation, the law on patentability of inventions involving “principles of nature” in Australia has yet to be considered judicially, but that is about to change, says Grant Shoebridge of Shelston IP. 16 August 2016
Americas
Dexcel Pharma, an Israel-based company, has sought a declaration of non-infringement against four Takeda patents. 15 August 2016
Americas
The US District Court for the District of Delaware has ruled that pharmaceutical company UCB’s patent covering epilepsy drug Vimpat is valid, after it was challenged by generic drug makers. 15 August 2016
Americas
Horizon Pharma has filed a complaint against Actavis accusing it of infringing three of patents for the Vimovo (naproxen/esomeprazole magnesium) drug. 12 August 2016